Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more.

Jiangsu Synthgene Biotechnology Co. Ltd. has synthesized platinum complexes acting as radiosensitizers reported to be useful for the treatment of cancer.

Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Chengdu Qingsheng Biopharmaceutical Co. Ltd. has described cannabinoid CB1 receptor antagonists reported to be useful for the treatment of obesity.

Idorsia Pharmaceuticals Ltd. has divulged macrocyclic compounds acting as cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.

Shenzhen Bay Laboratory has identified compounds reported to be useful for the treatment of cancer, eye, cardiovascular, metabolic, autoimmune, inflammatory, neurological and dermatological disorders.

Genescience Pharmaceuticals Co. Ltd. has synthesized sterols acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors reported to be useful for the treatment of endometriosis.

Daewon Pharm Co. Ltd. has disclosed tricyclic derivatives acting as reversible H+/K+-ATPase inhibitors reported to be useful for the treatment of gastroesophageal reflux disease.

Ileadbms Co. Ltd. has described son of sevenless homolog 1 (SOS1)/GTPase KRAS G12D mutant interaction and SOS1/GTPase KRAS G12C mutant interaction inhibitors reported to be useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome and more.

Shattuck Labs Inc. has divulged oligopeptides acting as E3 ubiquitin-protein ligase TRIM7 (GNIP; RNF90) inhibitors reported to be useful for the treatment of cancer, infections and inflammatory disorders.